APA (7th ed.) Citation

Liu, G., Xue, J., Wang, Y., Liu, Z., Li, X., Qu, D., . . . Yang, H. (2023). A randomized, open-label, two-cycle, two-crossover phase I clinical trial comparing the bioequivalence and safety of afatinib and Giotrif® in healthy Chinese subjects. Journal of cancer research and clinical oncology, 149(6), 2585-2593. https://doi.org/10.1007/s00432-022-04148-1

Chicago Style (17th ed.) Citation

Liu, Guangwen, et al. "A Randomized, Open-label, Two-cycle, Two-crossover Phase I Clinical Trial Comparing the Bioequivalence and Safety of Afatinib and Giotrif® in Healthy Chinese Subjects." Journal of Cancer Research and Clinical Oncology 149, no. 6 (2023): 2585-2593. https://doi.org/10.1007/s00432-022-04148-1.

MLA (9th ed.) Citation

Liu, Guangwen, et al. "A Randomized, Open-label, Two-cycle, Two-crossover Phase I Clinical Trial Comparing the Bioequivalence and Safety of Afatinib and Giotrif® in Healthy Chinese Subjects." Journal of Cancer Research and Clinical Oncology, vol. 149, no. 6, 2023, pp. 2585-2593, https://doi.org/10.1007/s00432-022-04148-1.